TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05761535

Intervention type: RADIATION
Intervention: Magnetic Resonance (MR) and positron emission tomograph (PET) imaging analyses
Description: Regarding the neurological MR protocol, the following may be acquired:~* 3D T1 and T2 high-resolution sequences, acquired in a specific plane and Multiplanar reformation (MPR) reconstructed in the remaining orthogonal planes, for morphological assessment of the different structures under examination;~* diffusion sequences for the evaluation of the connection between different areas within a specific organ;~* perfusion sequences (ASL, arterial spin labeling) for the evaluation of perfusion without ev mdc administration;~* susceptibility sequences for noninvasive assessment of vasculature and deposits of iron.

Intervention type: RADIATION
Intervention: Magnetic Resonance (MR) and positron emission tomograph (PET) imaging analyses
Description: Regarding the neurological MR protocol, the following may be acquired:~* 3D T1 and T2 high-resolution sequences, acquired in a specific plane and Multiplanar reformation (MPR) reconstructed in the remaining orthogonal planes, for morphological assessment of the different structures under examination;~* diffusion sequences for the evaluation of the connection between different areas within a specific organ;~* perfusion sequences (ASL, arterial spin labeling) for the evaluation of perfusion without ev mdc administration;~* susceptibility sequences for noninvasive assessment of vasculature and deposits of iron.
Study: NCT02080702

Intervention type: DEVICE
Intervention: Monosyn
Description: Monosyn will be used to perform the gastrointestinal anastomoses
Study: NCT04161339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400mg/daily of hydroxychloroquine for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Amido pills/daily for 8 weeks
Study: NCT04519606

Intervention type: PROCEDURE
Intervention: Optimal lung compliance during OLV
Description: Stepwise increase of tidal volume from 4 ml/kg PBW to 7 ml/kg PBW during OLV to determine the optimal tidal volume at the level the the pressure-volume loop reaches upper refection point where the peak airway pressure at or just below 30 cmH2O
Study: NCT03815045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark-based lumbar puncture
Description: Traditional landmark based lumbar puncture involves palpating spinous processes on the back and finding the inter-spinous space which is the site of needle entry to gain access to the thecal sac. Finding this space may be difficult by palpation, especially when subjects undergoing the procedure are obese, elderly, have had prior back surgery, or if the patient is positioned incorrectly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided lumbar puncture
Description: Ultrasound guided lumbar puncture is a novel technique being increasingly utilized by emergency physicians, pediatricians and anesthesiologists. In this technique, an ultrasound probe is used to visualize the inter-spinous space. This space can be marked on the skin as the potential point of entry. This could potentially make it easier when patient factors make it difficult to palpate and find the site of entry.
Study: NCT03346356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teenagers as cross-age SHCP teachers for younger youth
Description: Implementation of the SHCP using teenagers as cross-age teachers for younger youth
Study: NCT03254303

Intervention type: OTHER
Group type: OTHER
Intervention: Difficulty of catheterization in group 60 s

Intervention type: OTHER
Group type: OTHER
Intervention: Difficulty of catheterization in group 90 s

Intervention type: OTHER
Group type: OTHER
Intervention: Difficulty of catheterization in group 120 s
Study: NCT02410915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Assistive Limb (HAL); gait training
Description: Training with HAL is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group; Conventional gait training
Description: Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
Study: NCT04493515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Oxytocin
Description: Administration of oxytocin orally (24 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Administration of placebo orally (24 IU)
Study: NCT03970889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Klue
Description: Klue is a software program the uses an Apple watch to detect hand motions which are indicative of eating.
Study: NCT05807503

Intervention type: DRUG
Intervention: Cerebrolysin
Description: Cerebrolysin administration in short period of time after TBI
Study: NCT02504203

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Denmark 1331 (Statens Serum Institute)
Description: See above
Study: NCT01792466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transpancreatic sphincterotomy
Description: A sphinctertome will be placed into the pancreatic duct over a guidewire and the sphincter will be cut in the direction of the bile duct
Study: NCT04416542

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Home Sleep Testing
Description: Two-night Home Sleep Tests (HSTs) will be conducted using commercially available Home Sleep Test equipment. The HST will be ordered by the clinical center through a HIPAA compliant HST service that has been selected by the study sponsor.~The HSTs will be scored and interpreted according to AASM Guidelines by board certified sleep physicians affiliated with the HST service. The HST will be scored using the 4% oxygen desaturation rule.
Study: NCT01544114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO 250/20
Description: 250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO 375/20
Description: 375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
Study: NCT02056132

Intervention type: OTHER
Intervention: Exhaled Breath Condensate
Description: Lab results of Exhaled Breath Condensate

Intervention type: OTHER
Intervention: Exhaled Breath Condensate
Description: Lab results of Exhaled Breath Condensate
Study: NCT01899885

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AHA (Acute Highrisk Abdominalsurgery): Optimized Course
Description: optimized course: Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~1. standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~2. GDT-LiDCO fluid management pre-, per- and postoperative~3. Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~4. Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively
Study: NCT03722888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smokeSCREEN video game
Description: smokeSCREEN video game is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
Study: NCT02411136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 623
Description: Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
Study: NCT01544114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO 500/20
Description: 500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
Study: NCT02411136

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
Study: NCT02905864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg (Saxenda)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide 3 mg placebo
Study: NCT03982654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bloomlife
Description: Women use the Bloomlife sensor to collect data throughout their pregnancy. The collected data is stored locally in the device, but it is not used to provide any feedback to the patients or to the clinical team. Therefore the use of the device doesn't have an impact on clinical decision making and patients' care.
Study: NCT01658930

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Hysterectomy + pelvic lymph node dissection
Description: This procedure may be performed abdominally, laparoscopically, robotically or vaginally. The uterus, cervix, medial 1/3 of parametria, 2cm of the uterosacral ligaments and upper 1-2cm of the vagina are to be removed en bloc. The uterine artery is ligated laterally to the ureters and the ureters are unroofed to the ureterovesical junction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple hysterectomy + pelvic lymph node dissection
Description: This procedure may be performed abdominally, laparoscopically, robotically or vaginally. Extrafascial hysterectomy involves removal of the uterus with cervix without adjacent parametria. The uterine arteries are transected medial to the ureters at the level of the isthmus and the uterosacral ligaments are transected at the level of the cervix. Surgeons should pay special attention to make sure that the whole cervix is removed. As such, a maximum of 0.5 cm of vaginal cuff can be removed to ensure the complete removal of the cervix.
Study: NCT02723591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Oral Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus immediate release
Description: Oral Capsule
Study: NCT02310399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus ABI541 Auditory Brainstem Implant
Description: Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus ABI541 Auditory Brainstem Implant
Description: Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
Study: NCT03786484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999
Description: Phosphodiesterase 10 inhibitor (PDE10i)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999
Description: Phosphodiesterase 10 inhibitor (PDE10i)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999
Description: Phosphodiesterase 10 inhibitor (PDE10i)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999
Description: Phosphodiesterase 10 inhibitor (PDE10i)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999
Description: Phosphodiesterase 10 inhibitor (PDE10i)
Study: NCT03618550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
Study: NCT00910390

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Slow freezing
Description: Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIT-Irvine
Description: Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
Study: NCT03618550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
Study: NCT00910390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vit-Vitrolife
Description: Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
Study: NCT02792127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Program for Social Anxiety
Description: This program will be completed from participants' homes using their own computers. This online format is based on a Cognitive Behaviour Therapy framework (CBT) and involves seven modules that ask participants to engage in a variety of thinking exercises and activities.
Study: NCT02324322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Training
Description: Exoskeleton Training (100 sessions - 1 hour, 4 - 5 sessions per week for 20 weeks) to enhance functional ambulation for persons with a spinal cord injury. To examine the effectiveness of exoskeleton assisted overground walking to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Biopsies
Description: Needle Biopsies for Quadricep Muscles will be performed to define changes in BMD and Bone structure with intensive exoskeleton assisted walking. This procedure includes having a trained physician make a small skin incision, after numbing the area over the muscle, and then removing a tiny sliver of muscle to study under the microscope. Three separate biopsies for one incision will be obtained. The biopsies will be performed at baseline, 7 days, and after the intervention.~To define changes in biochemical markers of bone metabolism with intensive exoskeleton-assisted walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI's will provide accurate assessments of muscle CSA of each lower limb (from above the origin of the iliopsoas to the insertion of the achilles tendon) to determine individual's muscle thigh and shank volume.
Study: NCT03618550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
Study: NCT01305629

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spiritual Self-Schema Therapy
Description: The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spiritual Self-Schema Therapy
Description: The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life.
Study: NCT02691663

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral bicarbonate supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00668564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days before Transplant Drug Frequency~* 4 Cyclophosphamide Once, given over 2 hours~* 3 Cyclophosphamide Once, given over 2 hours~* 2 Cyclophosphamide Once, given over 2 hours~* 1 Cyclophosphamide Once, given over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: Days before Transplant Drug Frequency~12 Campath-1H Once, given over 2 hours~11 Campath-1H Once, given over 2 hours~10 Campath-1H Once, given over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Days before Transplant Drug Frequency~9 Busulfan Four times per day~8 Busulfan Four times per day~7 Busulfan Four times per day~6 Busulfan Four times per day
Study: NCT02988388

Intervention type: PROCEDURE
Intervention: Lung biopsy/lobectomy
Description: Lung biopsies and lobectomies are not experimental. Participants will undergo a lung biopsy or a lobectomy as part of standard of care.
Study: NCT03618550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
Study: NCT03050684

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: vaginal washing will be not applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
Study: NCT03318367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Complete virtual reality education module